Rodriguez-Fonseca C, Amils R, Garrett R A
Institute of Molecular Biology, Copenhagen University, Denmark.
J Mol Biol. 1995 Mar 24;247(2):224-35. doi: 10.1006/jmbi.1994.0135.
Ribosomal binding sites were investigated for the diverse group of antibiotics: anisomycin, anthelmycin, blasticidin S, bruceantin, carbomycin, chloramphenicol, griseoviridin, narciclasine, T2 toxin, tylosin and virginiamycin M1 all of which are considered to inhibit the peptidyl transferase reaction by different mechanisms. The drugs also exhibit differing degrees of specificity for bacterial, archaeal and eukaryotic ribosomes despite a high level of conservation of sequence and secondary structure at the peptidyl transferase centre of the 23 S-like rRNAs. The drug binding sites were characterized by incubating each antibiotic with ribosomes from a bacterium, an archaeon and a eukaryote and chemically probing the 23 S-like rRNA. The complexity of the changes in reactivity ranged from one or two nucleotides (anthelmycin, narciclasine) to eight or nine (virginiamycin M1) and it was inferred, at least for those drugs producing complex changes, that they induce, and stabilize, a particular functional conformer in the peptidyl transferase centre. The results were correlated with literature data on both ribosomal ligand binding and the putative inhibitory mechanisms of the drugs, and the following inferences are made concerning the fine structure of the peptidyl transferase centre. (1) An irregular secondary structural motif, which includes unpaired A2439 (Escherichia coli numbering), lies close to the catalytic centre; (2) nucleotides A2451 and C2452 contribute to a site for the binding of the side chains of aromatic amino acids; (3) the P-substrate site encompasses U2585, U2506 and, possibly, a site in domain IV (A1787), and (4) the sequence A2058 to A2062 and nucleotide U2609 contribute to, or modulate, the start of the peptide channel. No drug effects were found that could be directly attributed to an A-site and the possibility is raised that, if it exists, it consists mainly of ribosomal proteins. However, two drugs T2 toxin and virginiamycin M1 protected the only nucleotide in the peptidyl transferase loop region (C2394) associated with the E-site. Finally, it is proposed that the putative sub-sites are physically separated, that some drugs bind to more than one of them, and that they are conformationally interdependent.
对多种抗生素的核糖体结合位点进行了研究,这些抗生素包括:茴香霉素、抗蠕霉素、杀稻瘟菌素S、鸦胆子素、碳霉素、氯霉素、灰黄霉素、水仙环素、T2毒素、泰乐菌素和维及尼亚霉素M1,所有这些抗生素都被认为通过不同机制抑制肽基转移酶反应。尽管在23S样rRNA的肽基转移酶中心序列和二级结构具有高度保守性,但这些药物对细菌、古细菌和真核生物核糖体也表现出不同程度的特异性。通过将每种抗生素与来自细菌、古细菌和真核生物的核糖体一起孵育,并对23S样rRNA进行化学探测,来表征药物结合位点。反应性变化的复杂性范围从一两个核苷酸(抗蠕霉素、水仙环素)到八九个(维及尼亚霉素M1),并且推断,至少对于那些产生复杂变化的药物,它们在肽基转移酶中心诱导并稳定一种特定的功能构象体。结果与关于核糖体配体结合和药物假定抑制机制的文献数据相关联,并就肽基转移酶中心的精细结构得出以下推论。(1)一个不规则的二级结构基序,包括未配对的A2439(大肠杆菌编号),位于催化中心附近;(2)核苷酸A2451和C2452构成一个芳香族氨基酸侧链结合位点;(3)P底物位点包括U2585、U2506,可能还有结构域IV中的一个位点(A1787),并且(4)序列A2058至A2062和核苷酸U2609对肽通道的起始有贡献或调节作用。未发现可直接归因于A位点的药物效应,并且提出如果A位点存在,它可能主要由核糖体蛋白组成。然而,两种药物T2毒素和维及尼亚霉素M1保护了肽基转移酶环区域中与E位点相关的唯一核苷酸(C2394)。最后,有人提出假定的亚位点在物理上是分开的,一些药物与其中不止一个亚位点结合,并且它们在构象上是相互依赖的。